Ivosidenib (AG120)

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
64 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1667
NCT Identifier
NCT03471260

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.